Overview
Indivior PLC is a pharmaceutical company based in the United Kingdom, primarily engaged in the development, manufacture, and sale of medications for the treatment of opioid dependence. A significant part of its product portfolio includes formulations like buprenorphine and naloxone, aimed at reducing opioid use and facilitating addiction recovery. One of its key products, Suboxone®, is a film medication designed for sublingual administration, which has considerably shaped the market for therapeutic solutions in opioid addiction. Indivior continues to focus on innovations in the addiction treatment field, investing in new treatments for expedited detoxification and sustained recovery, maintaining its prominence in addressing the complex challenges of addiction at both individual and community levels.
Basic Stats
The share price of Indivior PLC as of September 5, 2025 is $24.98 / share. This is an increase of 2.86% from the prior week. The market cap (or net worth) of Indivior PLC as of September 5, 2025 is $3,121.88 MM.
The Factor Analysis chart (below right) shows a view of Indivior PLC from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 3,121.88 MM |
| EV | 2,937.88 MM |
| Shares Out. | 125.00 MM |
| Earnings Date | |
| EPS (TTM) | 0.42 |
| Dividend Yield | |
| Ex-Dividend Date | 2016-06-16 |
| Borrow Rate | 0.41 |
| Short Shares Avail. | 1.50 MM |
| Short Interest | 6.64 MM |
| Short Float | 7.40 % |
| Days to Cover | 4.26 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 125.20 % |
| Volatility (1 yr) | 0.56 |
| Beta | 0.74 |
| Sharpe Ratio (1 yr) | 2.15 |
| Sortino Ratio (1 yr) | 3.70 |
| PE Ratio | 58.90 |
| Price/Book | -12.15 |
| Price/TBV | -11.83 |
| Book/Market | -0.08 |
| EBIT/EV | 0.04 |
| EBIT(3yr avg)/EV | -0.02 |
| ROA | 0.03 |
| ROE | |
| ROIC | 0.49 |
| CROIC | 1.91 |
| OCROIC | 1.88 |
| Implied Volatility | 32.08 % |
| Put/Call OI Ratio | 0.02 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Indivior PLC is $14.88. The forecasts range from a low of $13.16 to a high of $16.84. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Indivior PLC. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-07-09 | Deutsche | Buy | Reiterate | |
| 2023-06-05 | Jefferies | Buy | Reiterate | |
| 2023-02-16 | Numis | Buy | Reiterate | |
| 2022-03-25 | Morgan Stanley | Equal Weight | Initiate | |
| 2021-06-30 | Numis | Reiteration | Reiterate | |
| 2021-01-28 | Jefferies | Buy | Reiterate | |
| 2021-01-26 | Citigroup | Buy | Reiterate | |
| 2021-01-19 | Jefferies | Buy | Reiterate | |
| 2020-06-17 | Jefferies | Hold | Reiterate | |
| 2019-05-02 | Citigroup | Neutral | Reiterate | |
| 2019-04-10 | RBC Capital Markets | Sector Perform | Reiterate | |
| 2019-02-05 | Numis | Buy | Reiterate | |
| 2018-12-18 | Numis | Buy | Reiterate | |
| 2018-11-21 | Jefferies | Buy | Hold | Downgrade |
| 2018-11-02 | RBC Capital Markets | Outperform | Reiterate | |
| 2018-09-27 | Numis | Buy | Reiterate | |
| 2018-06-20 | RBC Capital Markets | Outperform | Reiterate | |
| 2018-06-15 | Jefferies | Buy | Reiterate | |
| 2018-05-02 | Numis | Buy | Reiterate | |
| 2018-03-23 | RBC Capital Markets | Outperform | Reiterate | |
| 2017-12-01 | RBC Capital Markets | Outperform | Reiterate | |
| 2017-11-09 | Morgan Stanley | Equal-weight | Reiterate | |
| 2017-11-02 | Numis | Buy | Reiterate | |
| 2017-09-05 | Citigroup | Neutral | Reiterate | |
| 2017-08-03 | RBC Capital Markets | Outperform | Reiterate | |
| 2017-07-27 | Numis Securities | Buy | Reiterate | |
| 2017-07-11 | Numis Securities | Buy | Reiterate | |
| 2017-05-31 | Numis Securities | Buy | Reiterate | |
| 2017-05-04 | Numis Securities | Buy | Reiterate | |
| 2017-03-02 | Citigroup | Neutral | Reiterate | |
| 2017-02-27 | Jefferies | Buy | Reiterate | |
| 2017-02-22 | Numis Securities | Buy | Reiterate | |
| 2017-02-03 | Numis | Buy | Reiterate | |
| 2017-02-03 | Deutsche Bank | Buy | Reiterate | |
| 2016-12-16 | Jefferies | Buy | Reiterate | |
| 2016-12-12 | Deutsche Bank | Buy | Reiterate | |
| 2016-11-15 | Deutsche Bank | Buy | Reiterate | |
| 2016-11-07 | Jefferies | Buy | Reiterate | |
| 2016-11-03 | Numis | Buy | Reiterate | |
| 2016-11-03 | Deutsche Bank | Buy | Reiterate | |
| 2016-10-26 | Numis | Buy | Reiterate | |
| 2016-08-22 | Jefferies | Buy | Reiterate | |
| 2016-08-17 | Numis | Buy | Reiterate | |
| 2016-08-09 | RBC Capital Markets | Sector Perform | Reiterate | |
| 2016-07-26 | Jefferies | Buy | Reiterate | |
| 2016-06-29 | Jefferies | Buy | Reiterate | |
| 2016-06-06 | Jefferies | Buy | Reiterate | |
| 2016-05-04 | Citigroup | Buy | Reiterate | |
| 2016-04-29 | Jefferies | Buy | Reiterate | |
| 2016-03-09 | RBC Capital Markets | Underperform | Reiterate | |
| 2016-03-07 | Citigroup | Buy | Reiterate | |
| 2016-02-01 | Deutsche Bank | Buy | Reiterate | |
| 2015-11-25 | Citigroup | Buy | Reiterate | |
| 2015-11-19 | Jefferies | Buy | Reiterate | |
| 2015-07-24 | Morgan Stanley | Equal-weight | Reiterate | |
| 2015-07-15 | Citigroup | Buy | Reiterate | |
| 2024-12-17 | Jefferies | Buy | Reiterate | |
| 2024-09-05 | Deutsche | Buy | Reiterate | |
| 2025-03-06 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-08-06 | HC Wainwright & Co. | Buy | Initiate | |
| 2025-08-27 | Craig-Hallum | Buy | Buy | Maintains |
| 2025-06-30 | Craig-Hallum | Buy | Buy | Maintains |
